NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
- Active, not recruiting
- Dec 19, 2019
- 1 min read
NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)
To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device.
To evaluate the pharmacokinetics (PK) of SC and IV isatuximab
Sponsor
ClinicalTrials.gov Identifier: NCT05405166
Official Title: A Multi-center, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Efficacy of Subcutaneous and Intravenous Isatuximab (SAR650984) in Combination With Pomalidomide and Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
First Posted : August 6, 2019
Click here to see details on ClinicalTrials.gov
Drug: isatuximab SAR650984 IV
Drug: pomalidomide
Drug: dexamethasone
Drug: isatuximab SAR650984 SC
Device: Investigational injector device
Locations
United States, Arizona
United States, California
United States, Ohio
Australia, New South Wales
Australia, Victoria
Europe
Asia
Belgium
France
Japan
Spain